Patents by Inventor Olivier Laurent

Olivier Laurent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TL1A ANTIBODY COMPOSITIONS AND METHODS OF TREATMENT IN THE LUNG
    Publication number: 20240336691
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of diseases and/or conditions in the lung.
    Type: Application
    Filed: February 17, 2022
    Publication date: October 10, 2024
    Inventors: Allison LUO, Olivier LAURENT, Ernesto J. MUNOZ, Janine BILSBOROUGH, Bradley HENKLE, Stephan R. TARGAN, Dermot P. MCGOVERN
  • COMPOSITIONS COMPRISING HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF
    Publication number: 20240309104
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: February 17, 2022
    Publication date: September 19, 2024
    Inventors: Allison LUO, Lauren OTSUKI, Mark MANNING, Robert PAYNE, Olivier LAURENT, Janine BILSBOROUGH, Bradley HENKLE, Stephan R. TARGAN
  • ANTI-CD30L ANTIBODIES AND USES THEREOF
    Publication number: 20240254246
    Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: February 16, 2022
    Publication date: August 1, 2024
    Inventors: Jessie-Farah FECTEAU, Mark RENSHAW, Johan FRANSSON, Olivier LAURENT, Burton BARNETT
  • ANTI-CD30L ANTIBODIES AND USES THEREOF
    Publication number: 20240092923
    Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: November 15, 2023
    Publication date: March 21, 2024
    Inventors: Jessie-Farah FECTEAU, Mark RENSHAW, Johan FRANSSON, Olivier LAURENT, Burton BARNETT
  • Anti-CD30L antibodies and uses thereof
    Patent number: 11866505
    Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: August 26, 2022
    Date of Patent: January 9, 2024
    Assignees: PROMETHEUS BIOSCIENCES, INC., DR. FALK PHARMA GMBH
    Inventors: Jessie-Farah Fecteau, Mark Renshaw, Johan Fransson, Olivier Laurent, Burton Barnett
  • ANTI-CD30L ANTIBODIES AND USES THEREOF
    Publication number: 20230060624
    Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: August 26, 2022
    Publication date: March 2, 2023
    Inventors: Jessie-Farah FECTEAU, Mark RENSHAW, Johan FRANSSON, Olivier LAURENT, Burton BARNETT
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20210238159
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: April 15, 2021
    Publication date: August 5, 2021
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 10988454
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: April 27, 2021
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 10981890
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: April 20, 2021
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 10844042
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: November 24, 2020
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 10844041
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: November 24, 2020
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • MEMBRANE EMULSIFICATION DEVICE FOR MICROSPHERE CREATION
    Publication number: 20200353419
    Abstract: The present disclosure is directed to cross-flow membrane emulsification devices. The devices disclosed herein can have a continuous phase plate, a dispersed phase plate, an outlet, and a chamber. The chamber is located between the continuous phase plate and the dispersed phase plate and is bisected by a membrane with a plurality of pores. The chamber can include at least one channel on a first side of the membrane formed from at least one groove in the continuous phase plate and the membrane. In addition, the chamber can also include a cavity on a second side of the membrane formed in the dispersed phase plate.
    Type: Application
    Filed: November 21, 2018
    Publication date: November 12, 2020
    Applicant: Dauntless 1, Inc.
    Inventors: Olivier LAURENT, Joel F. MARTIN, Bradley J. SARGENT, Andrew SCHERER, Brian MCMANUS
  • Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 10829473
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: November 10, 2020
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • THERAPEUTIC COMPOUND FORMULATIONS
    Publication number: 20200281857
    Abstract: Provided herein are microspheres (e.g., single emulsion microspheres) comprising a therapeutic compound or pharmaceutically acceptable salt thereof, one or more polymers, and optionally a polyol, as well as methods of preparation, methods of use, and pharmaceutical compositions related thereto.
    Type: Application
    Filed: November 21, 2018
    Publication date: September 10, 2020
    Applicant: Dauntless 1, Inc.
    Inventors: Olivier LAURENT, Joel F. MARTIN
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20200277273
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20200277274
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20200277276
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE
    Publication number: 20200277275
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • PEPTIDE COMPOSITIONS AND METHODS OF USE
    Publication number: 20200197494
    Abstract: Provided herein are pharmaceutical compositions containing a therapeutic agent, an alkylglycoside, and pharmaceutically acceptable excipients and use of such compositions in the treatment of various conditions.
    Type: Application
    Filed: May 25, 2018
    Publication date: June 25, 2020
    Inventors: Olivier Laurent, Joel F. Martin, Sveinbjorn Gizurarson
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20190077784
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: September 12, 2018
    Publication date: March 14, 2019
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung